An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the virus from replicating inside cells. If future trials go well - now it has passed the first, Phase I, testing hurdle - it could become the longest-acting form of HIV prevention available.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

There are no right-leaning outlets covering this topic at this time.

'Lenacapavir' was developed by Gilead Sciences, a research-based biopharmaceutical company in the US. The drug works by blocking HIV from entering and multiplying in human cells. The trial included 40 participants, aged 18-55 years, who did not have HIV.

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024,...